91Ó°ÊÓ

The half-life of an isotope is the time it takes for half of the radioactive sample to decay. In radiotherapy, isotopes with an appropriate half-life are chosen so that the radioactive material can effectively deliver the radiation dose to the targeted area but also disintegrate and lose its radioactivity over time. An ideal half-life should neither be too short nor too long. A too short half-life would require frequent radioactive replacements, increasing the cost and exposure to radiation, while a too long half-life would increase the chances of the patient receiving excess radiation.

The type of radioactive decay determines the radiation emitted by the isotope during the decay process. There are several types of decay, such as alpha decay, beta decay, and gamma decay. In radiotherapy, the goal is to choose an isotope that emits radiation with enough energy to damage cancer cells, but not highly penetrating to protect healthy tissue around the target area. For example, alpha particles have a high linear energy transfer (LET) but a low penetration range, making them ideal for treating small and localized tumors, while gamma radiation has a low LET but a high penetration range, making it useful for treating larger and deeper-seated tumors.

During radioactive decay, unstable isotopes transform into more stable daughter isotopes. The properties of these daughter isotopes are essential to consider in radiotherapy. In some cases, the decay products themselves might be radioactive and emit harmful radiation that can damage healthy tissue. In such cases, consideration of the decay chain is necessary. The ideal radioisotope for radiotherapy should produce decay products that are either stable or have very short half-lives, so that the risk of harming the patient is minimized. In summary, the selection of an isotope for radiotherapy is strongly related to its half-life, mode of decay, and properties of products of decay. Each of these factors plays a crucial role in determining whether an isotope is suitable for radiotherapy, ensuring that the treatment is effective and safe for the patient.